Modern view on epidermal dysplasia carcinogenesis
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-3.13504Keywords:
actinic keratosis, epidermal dysplasia of the skin, polymorphism of genes, squamous cell carcinoma of the skinAbstract
Summary. Squamous cell carcinoma of the skin develops from the spectrum of facultative precancerous conditions, which in the course of malignant transformation through cancer stage in situ without early treatment fully transform into invasive squamous cell carcinoma. According to classical model of carcinogenesis, the transformation of actinic keratosis into squamous cell carcinoma of the skin occurs due to a mutation in one gene, more often a tumor suppressor, and undergoes a stage of development with lack of control of cell cycle. The aim of the research is to supplement current knowledge of genetic determination of pathogenetic mechanisms of epidermal dysplasia of the skin by studying the genetic determinant in the skin lesion of varying degrees of malignancy. Materials and Methods: We analyzed 85 skin bioptates of patients with epidermal dysplasia of the skin (Gr 1 — 43 patients with actinic keratosis; Gr 2 — 21 patients with non-invasive squamous cell carcinoma of the skin; Gr 3 — 21 patients with invasive squamous cell carcinoma of the skin) by molecular genetic testing of gene polymorphisms: TP53 (G13494A), L-myc (T3109G), TNF-α (G308A) in tumor tissue. The histological examination revealed the levels of dysplasia of the epidermis. Results: In case of the same disease duration in patients of Gr1/Gr3, L-myc (3109TT) is a genetic component of malignant transformation of epithelial skin cells (p = 0.004) and the development of invasive squamous cell carcinoma. Other variants of 3109TG and 3109GG genes do not have such prognostic value for the risk of skin cancer compared to 3109TT. Significant differences were found in the distribution of (13494GA) when comparing Gr 1 with Gr 3 (p = 0.014) and Gr 2 with Gr 3 (p = 0.038). A significant increase in the distribution of 13494GA genotype was revealed in patients with invasive form of keratinocyte intraepidermal neoplasia. 13494A allele was more likely to be detected in patients of Gr 3 compared to Gr 2 (p = 0.030) that proves the association of this allele with the development of invasive malignancies of the skin. The association of 308GG genotype and TNF-α (308G) allele with the development of malignant skin lesions was found. Comparing the distribution of 308G allele in patients of Gr 1 and Gr 2, we found its significant increase in patients of Gr 1. Comparative analysis of gene polymorphism with tumor invasion level showed a significant difference only in 308GG genotype between patients with grade III of KIN (keratinocyte intraepidermal neoplasia) in Gr 2 and patients with KIN III of Gr 1 (p = 0.007), and 308GA between patients with KIN III of Gr 2 and KIN III of Gr 1 (p = 0.027). Conclusions. Our work has supplemented modern vision of genetic component in pathogenetic mechanism of the development of epidermal dysplasia of the skin. Thus, the association of L-myc (3109TT) with the development of malignant skin lesions of different invasiveness and the modifying effect of TNF-α (G308A) and TP53 (G13494A) gene variants on pathological transformation in the focus of EDS depending on the level of epithelial dysplasia was revealed.
References
Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001; 344: 975–83.
Böhm M, Wolff I, Scholzen TE, et al. Аlpha-Melanocyte-stimulating hormone protects from ultraviolet radiation-induced apoptosis and DNA damage. J Biol Chem 2005; 280: 5795–802.
Salasche SJ. Epidemiology of actinic keratosis and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 4–7.
Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523–30.
Ratushny V, Gober MD, Hick R, et al. From keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin Invest 2012; 122: 464–72.
Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queens land community. J Invest Dermatol 2000; 115: 273–7.
Memon AA, Tomenson JA, Bothwell J, et al. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154–9.
Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23–4.
Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1: 795–7.
Marks R. An overview of skin cancers. Incidence and causation. Cancer 1995; 75: 607–12.
Mittelbronn MA, Mullins DL, Ramos-Caro FA, et al. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677–81.
Stockfleth E. Actinic keratoses. Cancer Treat Res 2009; 146: 227–39.
Ashton KJ, Weinstein SR, Maguire DJ, et al. Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization. Arch Dermatol 2003; 139: 876–82.
Quinn AG, Sikkink S, Rees JL. Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res 1994; 54: 4756–9.
Popp S, Waltering S, Herbst C, et al. UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 2002; 99: 352–60.
Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol 2006; 126: 2308–15.
Purdie KJ, Harwood CA, Gulati A, et al. Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs. J Invest Dermatol 2009; 129: 1562–8.
Purdie KJ, Lambert SR, Teh MT, et al. Allelic imbalances and microdeletions affecting the PTPRD gene in cutaneous squamous cell carcinomas detected using single nucleotide polymorphism microarray analysis. Genes Chromosomes Cancer 2007; 46: 661–9.
Durinck S, Ho C, Wang NJ, et al. Temporal dissection of tumorigenesis in primary cancers. Cancer Discov 2011; 1: 137–43.
Wang NJ, Sanborn Z, Arnett KL, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci USA 2011; 108: 17761–6.
Nindl I, Dang C, Forschner T, et al. Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer 2006; 5: 30.
Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol 2010; 146: 288–93.
Ra SH, Li X, Binder S. Molecular discrimination of cutaneous squamous cell carcinoma from actinic keratosis and normal skin. Mod Pathol 2011; 24: 963–73.
Lambert SR, Mladkova N, Gulati A, et al. Key differences identified between actinic keratosis and cutaneous squamous cell carcinoma by transcriptome profiling. Br J Cancer 2014; 110: 520–9.
Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366–74.
Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 10124–8.
Jiang W, Ananthaswamy HN, Muller HK, et al. p53 protects against skin cancer induction by UV-B radiation. Oncogene 1999; 18: 4247–53.
Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26: 1657–67.
Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010; 375: 673–85.
Farshchian M. Roles of novel biomarkers in progression of cutaneous squamous cell carcinoma. Turku: Painosalama Oy, 2015. 16 p.
Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009; 15: 425–30.
Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol 2013; 68: S10–9.
South AP, Purdie KJ, Watt SA, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J Invest Dermatol 2014; 134: 2630–8.
Pierceall WE, Goldberg LH, Tainsky MA, et al. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 1991; 4: 196–202.
Spencer JM, Kahn SM, Jiang W, et al. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995; 131: 796–800.
Lim YZ, South AP. Tumour-stroma crosstalk in the development of squamous cell carcinoma. Int J Biochem Cell Biol 2014; 53: 450–8.
Kivisaari A, Kähäri VM. Squamous cell carcinoma of the skin: Emerging need for novel biomarkers. World J Clin Oncol 2013; 4: 85–90.
Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146: 283–7.
Schmults CD, Karia PS, Carter JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013; 149: 541–7.
Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and Treatment of Invasive Squamous Cell Carcinoma of the Skin: European Consensus-based Interdisciplinary Guideline: http://www.euroderm.org/edf/index.php /edf-guidelines/category/5-guidelines-miscellaneous, 2014.
Suiqing C, Min Z, Lirong C. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 2005; 32: 354–60.
Koseki S, Aoki T, Ansai S, et al. An immunohistochemical study of E-cadherin expression in human squamous cell carcinoma of the skin: relationship between decreased expression of E-cadherin in the primary lesion and regional lymph node metastasis. J Dermatol 1999; 26: 416–22.
Behrens P, Rothe M, Wellmann A, et al. The Ets-1 transcription factor is upregulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol 2001; 194: 43–50.
Naito S, Shimizu S, Matsuu M, et al. Ets-1 upregulates matrix metalloproteinase-1 expression through extracellular matrix adhesion in vascular endothelial cells. Biochem Biophys Res Commun 2002; 291: 130–8.
Keehn CA, Smoller BR, Morgan MB. Ets-1 immunohistochemical expression in non-melanoma skin carcinoma. J Cutan Pathol 2004; 31: 8–13.
Kerkelä E, Ala-aho R, Klemi P, et al. Metalloelastase (MMP-12) expression by tumour cells in squamous cell carcinoma of the vulva correlates with invasiveness, while that by macrophages predicts better outcome. J Pathol 2002; 198: 258–69.
Johansson N, Airola K, Grenman R, et al. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151: 499–508.
Airola K, Johansson N, Kariniemi AL, et al. Human collagenase-3 is expressed in malignant squamous epithelium of the skin. J Invest Dermatol 1997; 109: 225–31.
Ala-aho R, Ahonen M, George SJ, et al. Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo. Oncogene 2004; 23: 5111–23.
Impola U, Jeskanen L, Ravanti L, et al. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol 2005; 152: 720–6.
Gözü A, Ergen A, Dayicioglu D, et al. L-myc polymorphism in head and neck nonmelanoma skin and lower lip cancers. Arch Otolaryngol Head Neck Surg 2008; 134: 725–8.
Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004–16.
Yaylim-Eraltan I, Bozkurt N, Ergen A, et al. L-myc gene polymorphism and risk of thyroid cancer. Exp Oncol2008; 30: 117–20.
Shih CM, Kuo YY, Wang YC, et al. Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases. Lung Cancer 2002; 36: 125–32.
Dolcetti R, Pelucchi S, Maestro R, et al. Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx. Eur Arch Otorhinolaryngol 1991; 248: 279–85.
Weston A, Ling-Cawley HM, Caporaso NE, et al. Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis (Lond) 1994; 15: 583–7.
Aarnio M, Mustonen H, Mecklin JP, et al. Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med 1998; 30: 75–80.
de Luis DA, Sagrado MG, Vallejo LA, et al. Influence of G308A polymorphism of tumor necrosis factor-alpha gene on inflammatory markers in postsurgical head and neck cancer patients with early enteral nutrition. Nutrition 2007; 23: 529–32.
Hehlgans T, Pfeffer K. The intriguing biology of the tumor necrosis factor/tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology 2005; 115: 1–20.
Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 4461–6.
Balkwill F. TNF-α in promotion and progression of cancer. Cancer and Metastasis Rev 2006; 25: 409.
Cockerell CJ, Wharton JR. New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J Drugs Dermatol 2005; 4: 462–7.
Sudhir N, Badaruddoza, Beri A, Kaur A. Association of tumor necrosis factor-alpha 308G/A polymorphism with recurrent miscarriages in women. J Hum Reprod Sci 2016; 9: 86–9.
Spinola M, Nomoto T, Manenti G. Linkage disequilibrium pattern in the L-myc gene in Italian and Japanese non-small-cell lung-cancer patients. Int J Cancer 2001; 95: 329–31.
Wasylishen AR, Stojanova A, Oliveri S, et al. New model systems provide insights into Myc-induced transformation. Oncogene 2011; 30: 3727–34.
Dang CV. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp Quant Biol 2011; 76: 369–74.
Spinola М, Pedotti Р, Dragani ТА, et al. Meta-analysis suggests association of L-myc EcoRI polymorphism with cancer prognosis. Clin Cancer Res 2004; 10: 4769–75.
Sauka C, Kohút A, Kundrát I, et al. Polymorphism of gene p53 and apoptosis in patients with malignant lung disease-our observation. Clin Oncol 2008; 21: 98–103.
Mechanic LE, Bowman ED, Welsh JA, et al. Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol Biomarkers Prev 2007; 16: 214–22.
Stengel А, Schnittger S, Weissmann S. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood 2014; 124: 251–8.
Marcel V, Dichtel-Danjoy ML, Sagne C, et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 2011; 18: 1815–24.
Biros E, Kohút A, Biros I, et al. A link between the p53 germ line polymorphisms and white blood cells apoptosis in lung cancer patients. Lung Cancer 2002; 35: 231–5.
Zheng W, Zhang S, Zhang S. The relationship between tumor necrosis factor-α polymorphisms and gastric cancer risk: An updated meta-analysis. Biomed Rep 2017; 7: 133–42.
Camargo MC, Mera R, Correa P, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: A meta-analysis. Cancer Epidemiol Biomarkers 2006; 15: 1674–87.
Gorouhi F, Islami F, Bahrami H, et al. Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br J Cancer 2008; 98: 1443–51.
Goldenberg G. Treatment considerations in actinic keratosis. JEADV 2017; 31: 12–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
